The misidentified cell line on which Heat Biologics Inc. based its cancer therapy HS-410 (vesigenurtacel-L) represents "a labeling problem that occurred very early in development," chief scientific officer Taylor Schreiber told BioWorld Today, and the paperwork matter should be resolved quickly with the FDA.